SAN DIEGO, Sept. 27, 2022 /PRNewswire/ — Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Firm”), a biopharmaceutical firm targeted on the event of recent strong tumor most...
Presently opening websites for Part III research of nomacopan in bullous pemphigoid (BP). Part III research of nomacopan in extreme pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) open...